Use Of 5α-Reductase Inhibitors And Survival Of Esophageal And Gastric Cancer In A Nationwide Swedish Cohort Study
May 2023
in “
Acta Oncologica
”
Studysummary This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →